Autor: |
Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B |
Jazyk: |
angličtina |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
Clinical Ophthalmology, Vol Volume 13, Pp 2461-2467 (2019) |
Druh dokumentu: |
article |
ISSN: |
1177-5483 |
Popis: |
Faye Horner, Peck-Lin Lip, Hannah Clark, Randhir Chavan, Ambreen Sarmad, Bushra Mushtaq Birmingham and Midland Eye Centre, Birmingham, UKCorrespondence: Bushra MushtaqBirmingham and Midland Eye Centre, City Hospital, Dudley Road, Birmingham B18 7QH, UKEmail bushramushtaq@nhs.netPurpose: To report the long-term clinical outcomes for patients with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy as part of a standardised treatment protocol in a real-world setting.Patients and methods: This is a retrospective audit of all treatment-naïve patients with nAMD who commenced a pro re nata (PRN) treatment regimen of intravitreal Ranibizumab from January to December 2009 and completed 8 years of follow-up in one single-treatment centre. Electronic medical notes were reviewed to evaluate the outcome measures. Outcome measures included progression of visual acuity (VA), central retinal thickness (CRT) and treatment frequency.Results: 95 eyes from 86 patients had complete data for 8 years of follow-up. Baseline median CRT was 295μm [IQR 254–349] and improved to 209μm [IQR 182–254] in year 8 (p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|